The Medical Advisor

Abstract Fenbendazole (FBZ), a benzimidazole-class anthelmintic primarily used in veterinary medicine, has garnered attention for its potential anticancer properties. This review examines anecdotal reports and case studies regarding the use of fenbendazole, an anthelmintic agent traditionally used in veterinary medicine, as a potential anticancer treatment in humans. A compilation of more than 300 case reports across various cancer types, including breast, lung, colorectal, prostate, and pancreatic cancers, is analyzed to assess the validity of these claims. While these anecdotal accounts suggest potential anticancer effects of fenbendazole, the lack of controlled clinical trials necessitates caution. Healthcare professionals should be consulted before considering fenbendazole as a treatment option. Keywords: Fenbendazole; Anthelmintic; Drug repurposing; Cancer treatment; Case reports; Ivermectin; Mebendazole Introduction Managing aggressive cancers r...

Abstract The antiparasitic agents fenbendazole, mebendazole and ivermectin have recently emerged as promising candidates for adjunctive cancer therapy due to their multifaceted anticancer mechanisms and favorable safety profiles. Fenbendazole and mebendazole, benzimidazole derivatives, exert antitumor effects primarily through microtubule disruption and metabolic interference, inducing cell cycle arrest and apoptosis. Ivermectin, a macrocyclic lactone, complements these actions by inhibiting oncogenic signaling pathways such as STAT3, Wnt/β-catenin, and AKT/mTOR, while modulating immune responses. This review synthesizes updated clinical case reports demonstrating tumor regression in refractory malignancies—particularly triple-negative breast cancer, pancreatic, and colorectal cancers—alongside emerging mechanistic insights and pharmacokinetic considerations. Despite encouraging anecdotal outcomes, evidence remains preliminary, underscoring the urgent need for rigorous clinical trials ...